BR112022008282A2 - Derivados de isoquinolinona, método para preparar os mesmos e composição farmacêutica para prevenir ou tratar doenças relacionadas à poli(adp-ribose) polimerase-1, que compreendem os mesmos como ingrediente ativo - Google Patents

Derivados de isoquinolinona, método para preparar os mesmos e composição farmacêutica para prevenir ou tratar doenças relacionadas à poli(adp-ribose) polimerase-1, que compreendem os mesmos como ingrediente ativo

Info

Publication number
BR112022008282A2
BR112022008282A2 BR112022008282A BR112022008282A BR112022008282A2 BR 112022008282 A2 BR112022008282 A2 BR 112022008282A2 BR 112022008282 A BR112022008282 A BR 112022008282A BR 112022008282 A BR112022008282 A BR 112022008282A BR 112022008282 A2 BR112022008282 A2 BR 112022008282A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
active ingredient
adp
ribose
polymerase
Prior art date
Application number
BR112022008282A
Other languages
English (en)
Inventor
Kim Eunhee
Park Changmin
Oh Sehwan
Kim Younghoon
Lee Juhee
Seol Jaehee
Shim Ahram
Kim Younggwan
Koo Tae-Sung
Jang Ki-Hong
Original Assignee
Digmbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digmbio Inc filed Critical Digmbio Inc
Publication of BR112022008282A2 publication Critical patent/BR112022008282A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pediatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

DERIVADOS DE ISOQUINOLINONA, MÉTODO PARA PREPARAR OS MESMOS E COMPOSIÇÃO FARMACÊUTICA PARA PREVENIR OU TRATAR DOENÇAS RELACIONADAS À POLI(ADP-RIBOSE) POLIMERASE-1, QUE COMPREENDEM OS MESMOS COMO INGREDIENTE ATIVO. A presente invenção refere-se a derivados de isoquinolinona, um método para preparar os mesmos e uma composição farmacêutica para prevenir ou tratar doenças relacionadas à poli(ADP-ribose) polimerase-1 (PARP-1) que contém os mesmos como um ingrediente ativo. Os derivados de isoquinolinona exibem um efeito inibidor de PARP-1 excelente a uma concentração de unidades nanomolares e ainda exibem um efeito citoprotetor excelente (efeito inibidor de apoptose) em doenças ou distúrbios oftálmicos, especificamente distúrbios de retina e, assim, podem ser usados com eficácia como uma composição farmacêutica para prevenir ou tratar doenças a PARP-1, por exemplo, doenças ou distúrbios oftálmicos, que contêm os mesmos como um ingrediente ativo.
BR112022008282A 2019-10-30 2020-10-29 Derivados de isoquinolinona, método para preparar os mesmos e composição farmacêutica para prevenir ou tratar doenças relacionadas à poli(adp-ribose) polimerase-1, que compreendem os mesmos como ingrediente ativo BR112022008282A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190136798 2019-10-30
PCT/KR2020/014947 WO2021086077A1 (ko) 2019-10-30 2020-10-29 이소퀴놀리논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
BR112022008282A2 true BR112022008282A2 (pt) 2022-07-26

Family

ID=75715420

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008282A BR112022008282A2 (pt) 2019-10-30 2020-10-29 Derivados de isoquinolinona, método para preparar os mesmos e composição farmacêutica para prevenir ou tratar doenças relacionadas à poli(adp-ribose) polimerase-1, que compreendem os mesmos como ingrediente ativo

Country Status (11)

Country Link
US (1) US20230027362A1 (pt)
EP (1) EP4053106A4 (pt)
JP (1) JP7512380B2 (pt)
KR (1) KR102293986B1 (pt)
CN (1) CN114929673A (pt)
AU (1) AU2020376697B2 (pt)
BR (1) BR112022008282A2 (pt)
CA (1) CA3158807A1 (pt)
IL (1) IL292466A (pt)
MX (1) MX2022005234A (pt)
WO (1) WO2021086077A1 (pt)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
WO2002094790A1 (fr) * 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Compose heterocyclique condense et son utilisation medicale
CN100390164C (zh) 2002-10-01 2008-05-28 三菱制药株式会社 异喹啉化合物及其医药用途
JP2009196973A (ja) * 2007-09-26 2009-09-03 Santen Pharmaceut Co Ltd キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤
ES2524787T3 (es) 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
US9051296B2 (en) * 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
RU2696572C2 (ru) * 2012-03-07 2019-08-05 Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение
WO2017013593A1 (en) 2015-07-22 2017-01-26 Lupin Limited Isoquinolinone derivatives as parp inhibitors
MX2018005515A (es) 2015-11-02 2018-08-01 Merck Patent Gmbh Derivados de 1,4-dicarbonil-piperidilo.
KR102030016B1 (ko) 2016-09-05 2019-10-08 충남대학교산학협력단 신규한 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
MA47165B1 (fr) * 2016-12-30 2021-06-30 Mitobridge Inc Inhibiteurs de la poly-adp-ribose polymérase (parp)
KR102017115B1 (ko) * 2018-05-15 2019-09-02 충남대학교산학협력단 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물

Also Published As

Publication number Publication date
US20230027362A1 (en) 2023-01-26
AU2020376697A1 (en) 2022-05-19
CA3158807A1 (en) 2021-05-06
JP2023506368A (ja) 2023-02-16
KR20210052330A (ko) 2021-05-10
IL292466A (en) 2022-06-01
WO2021086077A1 (ko) 2021-05-06
EP4053106A4 (en) 2023-12-06
CN114929673A (zh) 2022-08-19
AU2020376697B2 (en) 2024-03-14
EP4053106A1 (en) 2022-09-07
KR102293986B1 (ko) 2021-08-26
MX2022005234A (es) 2022-09-07
JP7512380B2 (ja) 2024-07-08

Similar Documents

Publication Publication Date Title
AR054229A1 (es) Metodos para tratar la angiogenesis ocular edema de retina, isquemia de retina y retinopatia diabetica usando inhibidores selectivos de rtk
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
BR112021017831A2 (pt) Derivados heteroaromáticos e aromáticos heterobicíclicos para o tratamento de distúrbios relacionados com ferroptose
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112017012402A2 (pt) derivados de 2,4-dioxo-quinazolina-6-sulfonamida como inibidores de parg
CR10041A (es) Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares
BR112016000546A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
MX2021011488A (es) Compuestos y usos de estos.
PH12016500715A1 (en) Di-isopropyl-phosphinoyl-alkane (dapa) compounds as topical agents for the treatment of sensory discomfort
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
BR112016006444A2 (pt) derivado de triazolopirazina e uso do mesmo
MX2024006769A (es) Compuestos y usos de los mismos.
MX2024000349A (es) Compuestos y usos de los mismos.
WO2015048188A8 (en) Modified fibroblast growth factors for the treatment of ocular disorders
BR112018014525A2 (pt) compostos que antagonizam receptor de adenosina a3, método para preparação dos mesmos e aplicação médica dos mesmos
BR112020014191A2 (pt) Unidade de controle transcricional (uct), construção de expressão, vetor, célula hospedeira, composição farmacêutica, uso de um vetor, método para tratamento ou prevenção de distúrbios da retina e vetores para uso
CL2023001580A1 (es) Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección
EP3639855A4 (en) COMPOUNDS HAVING CASPASE INHIBITORING ACTIVITY, PHARMACEUTICAL AGENT CONTAINING THEM FOR THE TREATMENT OR PREVENTION OF SYMPTOMS, DISORDERS OR DISEASES OF CORNEAL ENDOTHELIUM, AND APPLICATION OF SUCH PHARMACEUTICAL AGENT
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
BR112022008282A2 (pt) Derivados de isoquinolinona, método para preparar os mesmos e composição farmacêutica para prevenir ou tratar doenças relacionadas à poli(adp-ribose) polimerase-1, que compreendem os mesmos como ingrediente ativo
BR112016011727A2 (pt) Antagonistas de gastrina para o tratamento e prevenção de osteoporose
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
BR112021017829A2 (pt) Composto, e, composição farmacêutica para uso em prevenir ou tratar câncer